The Mayo Clinic Program in Precision Genomics Interventional Therapeutics

Mayo Clinic and its Department of Clinical Genomics as well as other aligned Departments and Programs are seeking exceptional physicians and scientists experts in the rapidly evolving field of genome editing and therapeutic delivery to drive innovation at the intersection of discovery translational clinical research and clinical practice to join our new and rapidly evolving Program in Precision Genomics: Interventional Therapeutics (PG-IT).

The PG-IT program at Mayo Clinic is a groundbreaking new initiative of highly innovative and creative scientists and physicians working collaboratively to advance next-generation molecular therapies by delivering genetically targeted treatments in vivo. We are building an accomplished team of leaders including scientists driving innovation in genome editing and physicians who can deliver customized new and novel genetic therapies to the patients we serve. We are seeking candidates who excel in collaborative team-oriented environments and demonstrate a strong commitment to advancing genomic medicine for improved patient outcomes. Qualified candidates joining the PG-IT program will collectively possess expertise in rare and complex disease genetics and genomics clinical-grade genomic sequencing multi-omic investigations interventional human genetics functional genomics innovative molecular therapeutics and human interventions and clinical trials including single patient expanded access investigational new drug (IND) development processes. These candidates will join our efforts to develop a comprehensive institutional program that unites laboratory discovery clinical genomics informatics and precision therapeutics thereby delivering transformative advancements for patients affected by genetic and genomic disorders including rare inherited and complex disorders and diseases.

The PG-IT program will build on tremendous strengths at Mayo Clinic including:

• The Mayo Clinic Artificial Intelligence (AI) Program driving the development of AI-based drug discovery predictive models large language models (LLMs) and AI agents within research and implemented into the Mayo Clinic clinical practice powered by unparalleled partnerships and compute capabilities (NVIDIA SuperPOD DGX B200).
• Mayo Clinic Platform (MCP; ) the worlds largest distributed federated healthcare data network with cloud-based storage of the fully digitized longitudinal patient records (including fully digitized radiographic images and pathology slide images and sophisticated laboratory diagnostics) and associated research data and biospecimens from >50M patients at Mayo Clinic and MCP partners worldwide.
• Exceptional research and clinical programs research infrastructure shared research resources and education and training programs to facilitate research in basic and clinical genomics and molecular engineering to precisely target genetic drivers of rare and complex conditions.
• A robust clinical research and clinical trials infrastructure that currently supports the delivery of the nations largest number of clinical trials to the patients we serve including new and novel and first in human therapies including cellular biologic and genetic therapies.
• Mayo Clinics unique collaborative ecosystem which includes an integrated clinical practice world-class research platforms and advanced infrastructure for gene and cell-based therapeutic development.

Our goals for the Mayo Clinic PG-IT program include in vivo human gene editing for rare and inherited genetic disorders and complex human diseases the acceleration of drug repurposing for genetically targeted indications and identifying the most promising novel gene-editing interventions to benefit patients. This will help accelerate discovery and apply cutting-edge innovations in real-world settings. Areas of opportunity span therapeutic development CRISPR- and RNA-based interventions genome engineering molecular diagnostics novel mechanisms and modes of delivery of genetic therapies in vivo and the deployment of genomics-enabled clinical care pathways for rare inherited and complex conditions.

Successful candidates will lead design and implement innovative genomic and translational approaches that improve patient outcomes while driving forward to the next generation of therapeutic and diagnostic discovery. These roles offer the opportunity to collaborate across Mayo Clinics extensive research and clinical networks including partnerships with the Mayo Clinic Laboratories the Advanced Diagnostics Laboratory extensive biopharma partnerships and collaborations and enterprise-wide precision medicine initiatives. Faculty will contribute to the development and integration of emerging genomic technologies into clinical and therapeutic pipelines helping to shape programs that influence local national and global practice in genomic medicine. As the PG-IT Program builds it will gain SAGE (Standards for Advanced Gene Editing) certification for the customized delivery of human genetic interventions.

Mayo Clinics values of teamwork collaboration and patient-centered care are foundational to deliver integrated research medical and surgical care for individuals with complex genetic and genomic conditions. Faculty members will receive academic appointments (Assistant Associate Full Professor and Consultant) within the Mayo Clinic College of Medicine and Science commensurate with experience scholarly contributions and leadership in clinical research or translational domains. Mayo Clinic is committed to supporting the long-term success of faculty through robust research infrastructure interdisciplinary mentorship and a culture that values innovation scientific excellence and transformative patient impact.

We are enthusiastic about the potential to work with visionary leaders in the field and look forward to the opportunity to make significant strides in genomic medicine together.

The Department of Clinical Genomics
The Department of Clinical Genomics at Mayo Clinic is a national leader in integrating advanced genomic science with patientcentered clinical care. Our mission is to individualize medicine through the development and application of cuttingedge genomic technologies that enable the prediction prevention diagnosis and treatment of both rare and common genetic conditions. By generating deep insights into each patients genomic architecture our teams drive innovative care strategies that improve outcomes and shape the future of precision medicine.

Clinical Genomics supports a broad spectrum of services including comprehensive family history assessments risk evaluations for hereditary conditions and wholeexome wholegenome and multiomic testing for complex and rare disorders. These programs are tightly integrated with enterprisewide research and clinical resources providing faculty with unparalleled access to worldclass platforms in sequencing functional genomics bioinformatics and emerging therapeutic modalities.
Our department operates through a highly collaborative multidisciplinary model bringing together medical geneticists PhD scientists certified genetic counselors nurses and allied specialists across Mayo Clinics practice and research environment. This seamless integration enables faculty to evaluate virtually any genetic condition coordinate advanced diagnostic workflows and partner with teams across the institution to translate discovery into meaningful clinical impact.

For faculty Clinical Genomics is an enterprise department spanning the three Mayo Clinic sites of Rochester Florida and Arizona and offers a dynamic and supportive environment in which to build innovative research programs engage in transformative clinical initiatives and contribute to Mayo Clinics enterprise commitment to advancing genomic medicine. Faculty benefit from strong institutional support access to robust research infrastructure the opportunity to collaborate across multiple campuses and the ability to contribute to initiatives that influence care on a national and global scale.

Mayo Clinic
For over 160 years the mission of Mayo Clinic has been to inspire hope and to promote health and healing through the integration of clinical practice research and education on behalf of the patients communities and learners we serve from across the nation and the world. Each of Mayo Clinics three Destination Medical Center (DMC) campuses in the United States are fully engaged in clinical practice innovative research and education and training. These three campuses referred to as the Mayo Clinic enterprise - include Rochester Minnesota (MCR); Jacksonville Florida (MCF); and Phoenix and Scottsdale Arizona (MCA). In addition Mayo Clinic fully owns and operates a community-based rural health care delivery system (the Mayo Clinic Health System; MCHS) which extends through 49 rural communities in southern Minnesota western Wisconsin and northeastern Iowa.

For the past eight years Mayo Clinic has been ranked as the No. 1 health system in the nation and the world with the most #1 ranked medical specialties by U.S. News & World Report Newsweek and other healthcare quality organizations. Each of the Mayo Clinic hospitals on the three Mayo Clinic campuses have also been consistently ranked as the #1 hospital and the #1 cancer center and cancer hospital in their respective state. Mayo Clinic also has the largest integrated organ transplant program in the nation and conducts more clinical trials driving research and testing new therapies and interventions compared to any other institution in the United 2025 with a staff of more than 85000 including more than 7300 physicians and scientific investigators Mayo Clinic cared for more than 1.3 million unique patients who came from all 50 U.S. states and 135 countries.

Mayo Clinic: The 2030 Bold. Forward. Strategic Plan
Health care has operated in an environment where patients have had the least control. Technology data-driven knowledge artificial intelligence (AI) consumerism and platform thinking will establish the next generation of health care. To thrive in this environment healthcare organizations must break through the old paradigm and transform scientific research and healthcare access and delivery on behalf of the patients we serve. By remaining true to its primary value the needs of the patient come first and the RICH TIES core values of Respect Integrity Compassion Healing Teamwork Innovation Excellence Stewardship Mayo Clinic is driving the transformation of biomedical research and health care through its 2030 Bold. Forward. Strategic Plan with the framework Cure Connect and Transform.

Cure.
Cure is dedicated to accelerating discovery translation and delivery of more cures for both chronic and acute diseases. Mayo Clinic is differentiating itself through the conduct of highly innovative discovery science and its translation to enable the delivery and diffusion of the next generation of diagnoses treatments and cures. This includes new in vivo and in vitro medical surgical and radiologic therapies and interventions delivered physically within our healthcare facilities and digitally and virtually in patients homes and community settings.

Connect.
Connect is focused on connecting people with data to create new knowledge and delivering scalable end-to-end solutions. This means making our healthcare delivery systems more accessible for patients but also easier for providers researchers and other partners to collaborate to conduct research and clinical practice to create new new programs such as Mayo Clinic Care Beyond Walls Cancer Care Beyond Walls (CCBW) and Clinical Trials Beyond Walls (CTBW) Mayo Clinic is creating a digital care delivery model that maintains a human touch.

Transform.
Transform means creating a new future for healthcare focused on a scalable AI-enabled platform for the conduct of research and care delivery. Mayo Clinic is driving the platform transformation of health care by creating Mayo Clinic Platform - what we believe is the first true large-scale platform in health care - and building highly innovative research and clinical programs including the Mayo Clinic Generative Artificial Intelligence (GenAI) Program.

Mayo Clinic Platform
To drive the platform transformation of healthcare Mayo Clinic has created the Mayo Clinic Platform (MCP) healthcares first comprehensive dynamic scalable AI-enabled research engine and patient care platform. Through MCP Mayo Clinic has created the worlds largest collaborative distributed federated healthcare data network (MCP Connect) with a cloud-based data architecture holding the longitudinal healthcare records of 54 million patients from across the world. Four MCP Connect network members are ranked among the worlds top 10 healthcare systems (Mayo Clinic University Health Network (UHN) University of Toronto/Princess Margaret Cancer Centre Sheba Health System of Israel and Singapore National Health (SingHealth)). From Mayo Clinic alone MCP holds the fully digitized longitudinal healthcare records from 15M Mayo Clinic patients including 705 million patient encounters 3.2 billion laboratory results 1.65 billion clinical notes 8.1 billion radiographic images (X-ray CT MRI PET) the worlds largest repository of digitized pathology slides (20 million) and 662 million diagnoses. The clinical data in MCP is further linked to repositories of patient biospecimens and highly annotated epidemiologic and research data sets facilitating scientific discovery and translation to clinical endpoints and the ability to build AI-driven predictive models to improve patient care. While each MCP partner holds its own secured privacy-protected patient healthcare data in its node in the network the creation of a shared data architecture for the network and an anonymized de-identified data layer facilitates rapid collaboration across the globe.

By applying our knowledge and expertise in the biological medical physical engineering computational sciences and AI to the worlds largest healthcare dataset in MCP we are driving innovative research in many diseases discovering new cures enhancing access to clinical trials and transforming how we deliver cancer care within our facilities and beyond our walls in patient homes and community settings. We are also making significant investments on our campuses to transform healthcare for all by seamlessly integrating physical spaces and digital capabilities and by harnessing AI robotics and automation to meet patients unmet and evolving needs. Our vision is to use our shared platforms to ensure that healthcare is accessible to all at any place and any time transcending geographic and physical barriers. We are sharing our knowledge globally impacting policy and partnering with others to create a healthier world.

Mayo Clinic Generative Artificial Intelligence (GenAI) Program
The Mayo Clinic GenAI Program is an extensive multifaceted initiative focused on integrating generative AI and agentic AI into clinical practice research and administration across the Mayo Clinic enterprise. With our technology partners (Google Microsoft NVIDIA and Cerebras) Gen AI is leveraging the vast patient data in Mayo Clinic Platform to create foundation models generative AI solutions and AI agents that improve clinical practice personalize patient care accelerate research discover new therapeutics and cures reduce administrative burden and transform healthcare. Mayo Clinic Gen AI investigators have developed 97 AI algorithms in clinical use with more than 270 algorithms in development.

To drive AI solutions Mayo Clinic has partnered with Microsoft and NVIDIA to develop one of the most advanced computing infrastructures of any academic healthcare system in the world with 264 graphics processing units (GPUs) and 168 GPUs in the July 2025 Mayo Clinic completed a pivotal step in development of our computing power with deployment of the NVIDIA SuperPOD DGX B200 in Mayo Clinics Discovery Square in Rochester MN that is accessible across the Mayo Clinic Enterprise. With scalability up to tens of thousands of GPUs the efficient liquid-cooled DGX GB200 rack-scale design leverages NVIDIA GB200 Grace Blackwell Superchips to tackle the state-of-the-art AI models needed for todays advanced generative AI applications that train on massive datasets such as multimodal imaging (CT MRI PET) and genomic sequencing data. This computing capability allows us to accelerate AI-driven drug discovery create visual applications perform high-resolution imaging analysis and train state-of-the-art foundation models that have trillions of parameters and must train on as much as a petabyte of data.

With our partners Mayo Clinic has developed several AI-powered foundational models. With Microsoft Research we have developed foundation models that can automatically generate reports from radiology images (CT scans and MRIs). With Cerebras Systems Mayo Clinic has built one of the first genomics foundational models (STRAND) that combines public data with Mayo Clinics patient data of germline genetic sequencing in more than 100000 patients. And with NVIDIA and Aignostics the Mayo Clinic Digital Pathology initiative is using AI to analyze its extensive archive of 20 million digitized slides and has developed a leading pathology foundation model (ATLAS) trained on more than 1.2 million histopathology whole-slide images to accelerate and enhance the accuracy of diagnostic digital pathology.

Research at Mayo Clinic
In an evolving scientific landscape driven by data and technological advances Mayo Clinics research strategy embodies an unwavering commitment to deliver innovative effective cures with speed precision and purpose. To achieve this Mayo Clinic Research is advancing a set of strategic priorities for research aligned with its Bold. Forward. vision to shape the future of healthcare.

Mayo Clinic is accelerating scientific discovery by enhancing and streamlining access to its vast biospecimen collection creating a more unified collaborative environment and empowering researchers across disciplines and parallel teams are building infrastructure to support the discoverability and utility of digitized data through centralized platforms including Mayo Clinic Platform and the Mayo Clinic Research Atlas - fostering greater collaboration and innovation within Mayo Clinic and beyond. These foundational capabilities are driving a broader paradigm shift: from reactive treatment to proactive prevention and interception of disease. Building on this vision Mayo Clinic is pioneering new means of early detection diagnosis and treatment for cancer and non-cancer disorders and for end-organ failure with goals to extend organ health spans. We are developing new solutions for cure and diagnostics through sophisticated technologies and designing novel clinical trials to test next-generation therapies. These efforts are converging to revolutionize the clinical trial landscape. Through automation digital strategies and deeper integration with clinical practice Mayo Clinic is significantly reducing clinical trial activation timelines expanding patient access and improving trial outcomes.

The Genesis initiative is a strategic imperative for the research shield which will drive bold advancements in transplantation and prevention of end-organ failure by creating new capabilities in in-vivo cellular engineering advanced cell therapies and bio artificial organ systems. Multidisciplinary teams across heart lung liver kidney bone marrow brain and soon pancreas are tackling the most pressing scientific and clinical challenges supported by cutting-edge tools like epigenetic editing RNA therapeutics and machine perfusion. Early-phase moonshot projects emerging from the Mayo Clinic Advanced Innovation Research program are already pioneering breakthroughs such as HLA-depleted hearts bioengineered lungs liver digital twins and ischemia-free heart transplants. The Department of Clinical Genomics will play a critical role in the success of these programs by driving innovative scientific discovery and enabling technologies and translational platforms that bridge discovery science with clinical application. By building strategic external partnerships and expanding its ecosystem of collaborators Mayo Clinic is accelerating discovery-to-translation pathways to deliver next-generation solutions to prevent end-organ failure and to deliver cures for patients.

These initiatives and the talented people behind them will bring life-changing innovations and cures to patients faster than ever before. That is why Mayo Clinic remains dedicated to recruiting and retaining a diverse dynamic research workforce and expanding its research infrastructure. With oversquare feet of research space across campuses in Arizona Florida and Minnesota and continued investment in growth Mayo Clinic is positioned to lead the next generation of medical discovery and deliver transformative care to patients worldwide.

Rochester Minnesota
Mayo Clinic is located in the heart of downtown Rochester Minnesota a dynamic city just 75 minutes south of the Twin Cities of Minneapolis and St. Paul. The city is consistently ranked among the best places to live in the United States because of its affordable cost of living healthy lifestyle excellent school systems and exceptionally high quality of life. Rochester is changing to become the worlds premier destination medical center as new buildings fill the skyline that pave the way for initiatives that are unleashing fresh possibilities and make the city a fantastic place to learn live and play. Distinguished by its culture of caring spirit of innovation and fascinating history Rochester is renowned for its scenic beauty relaxing pace and abundant dining shopping and entertainment options.

The Bold. Forward. Unbound. initiative is a $5 billion six-year transformation of Mayo Clinics downtown Rochester campus adding approximately 2.4 million square feet across five new buildings. This expansion reimagines care delivery through flexible future-oriented designs such as adaptable clinical spaces and integrated digital technologies. The initiative also involves extensive infrastructure upgrades and phased demolition to support a more connected patient-centered environment.

To stimulate the translation of discovery science to human applications facilitate collaboration with biotechnology industry and expand innovation networks Mayo Clinic has developed biotechnology research parks and healthcare innovation districts adjacent to each Mayo Clinic campus. Discovery Square is a 16-block district of downtown Rochester fostering collaborations between biotech industries and MCR investigators. One Discovery Square opened in 2019 with infrastructure for wet and dry laboratories and houses the Mayo Clinic Center for Regenerative Biotherapeutics (CRB). CRB is producing several novel cancer therapeutics (gene and virus therapies cancer vaccines novel CAR-T agents) which are being tested by Mayo Clinic investigators in clinical addition to CRB Discovery Square is now home to 35 biotechnology companies including Boston Scientific and Phillips.

Recruitment of Basic and Translational Discovery Scientists in Gene Editing

Required Qualifications

• PhD or equivalent degree with post-doctoral training in relevant scientific fields
• Demonstrated expertise in genetics and genomics in human cells and tissues and/or in relevant model systems
• Experience in developing or applying human and other model systems or diseasespecific cellular platforms
• Proven record of scholarly productivity including high quality peerreviewed publications and peer-reviewed funding and/or industry funding (or clear potential to gain future funding) leading to impactful research contributions
• Demonstrated creativity and innovation
• Ability to contribute to translational genomics programs that integrate discovery science with clinical or therapeutic applications
• Strong communication skills with the ability to collaborate across scientific clinical and operational teams

• Commitment to Mayo Clinics values including teamwork integrity innovation and patientcentered care

Preferred Qualifications

• Experience working in collaborative multidisciplinary research or clinical environments
• Experience in teaching and mentoring

Clinician Investigators in In Vivo Gene Editing and Therapeutic Delivery

Required Qualifications

• Board-certified MD MD/PhD or equivalent clinical degree with experience in clinical genetics and/or genomics
• Expertise in multiple human geneediting or therapeutic genomics modalities and in in vivo therapeutic delivery
• Proven record of scholarly productivity including high quality peerreviewed publications and sustained peer-reviewed funding and/or industry funding leading to impactful research contributions
• Demonstrated creativity and innovation
• Proven track record in innovative translational and clinical research including novel therapeutics and therapeutic development and in the design and conduct of human clinical trials particularly early phase and first-in-human human clinical trials and single patient INDs.
• Demonstrated academic leadership in research and clinical practice and programbuilding expertise
• Demonstrated ability to develop strategies and drive multidisciplinary teams to success

Preferred Qualifications

• Experience participating in multiinstitutional research networks or other large collaborative scientific initiatives
• Experience in teaching and mentoring